Press Releases33/2025・Trifork Group: Weekly report on share buyback By globenewswire June 9, 2025 0 0 33/2025・Trifork Group: Weekly report on share buyback Company announcement no. 33 / 2025Schindellegi, Switzerland – 9 June 2025 Source: https://www.globenewswire.com/news-release/2025/06/09/3095602/0/en/33-2025-Trifork-Group-Weekly-report-on-share-buyback.html TagsbuybackCH1111227810companyCopenhagen:TRIFORnewsREGreportsharesource Previous articleARKS forays into the world of fragrances with the launch of its debut scent ‘ARKS Day’Next articleChina’s Hangzhou High-Tech Zone (Binjiang) Wows Global Media with Sophisticated Digital Empowerment in Business, Life, and Beyond globenewswire Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations July 3, 2025 ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST July 3, 2025 ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST July 3, 2025 Blokees Becomes Exclusive Strategic Partner of “Journey of Light: A Glimpse into Ultraman’s 60th Anniversary” Exhibition July 3, 2025 First AML expands Tranche 2 leadership in Australia following major client wins across law and real estate July 3, 2025 Lake Chelan Health enters into Prime Vendor agreement with Medline July 3, 2025 Recent News ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations